301847-02-9

Basic information

• Product Name: Thieno[2,3-b]pyridine-2-carboxylic acid, 3-amino-4-phenyl-6-(2-thienyl)-, ethyl ester
• Synonyms: ethyl 3-amino-4-phenyl-6-(2-thienyl)thieno[2,3-b]pyridine-2-carboxylate
• CAS NO: 301847-02-9
• Molecular Formula: C₂₀H₁₆N₂O₂S₂
• Molecular Weight: 380.48324
• Mol File: 301847-02-9.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Thieno[2,3-b]pyridine-2-carboxylic acid, 3-amino-4-phenyl-6-(2-thienyl)-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Thieno[2,3-b]pyridine-2-carboxylic acid, 3-amino-4-phenyl-6-(2-thienyl)-, ethyl ester(301847-02-9)
• EPA Substance Registry System: Thieno[2,3-b]pyridine-2-carboxylic acid, 3-amino-4-phenyl-6-(2-thienyl)-, ethyl ester(301847-02-9)

Safety Data

• Hazardous Substances Data: 301847-02-9(Hazardous Substances Data)

Upstream product

• 88-15-3 2-Acetylthiophene 
• 105-39-5 chloroacetic acid ethyl ester 
• 100-52-7 benzaldehyde 
• 82127-11-5 4-phenyl-6-(thiophen-2-yl)-2-thioxo-1,2-dihydropyridine-3-carbonitrile 
• 3988-77-0 3-phenyl-1-thiophen-2-yl-propenone 
• 847976-22-1 ethyl 2-((3-cyano-4-phenyl-6-(thiophen-2-yl)pyridin-2-yl)thio)acetate 

Downstream Products

• 847976-36-7 3-Amino-4-phenyl-6-thiophen-2-yl-thieno[2,3-b]pyridine-2-carboxylic acid [1-(4-methoxy-phenyl)-meth-(E)-ylidene]-hydrazide 
• 847976-37-8 3-Amino-4-phenyl-6-thiophen-2-yl-thieno[2,3-b]pyridine-2-carboxylic acid [1-(4-chloro-phenyl)-meth-(E)-ylidene]-hydrazide 
• 847976-35-6 3-Amino-4-phenyl-6-thiophen-2-yl-thieno[2,3-b]pyridine-2-carboxylic acid [1-phenyl-meth-(E)-ylidene]-hydrazide 
• 847976-51-6 (3-amino-4-phenyl-6-thiophen-2-yl-thieno[2,3-b]pyridin-2-yl)-(3,5-dimethyl-pyrazol-1-yl)-methanone 
• 847976-58-3 3-hydrazinomethyleneamino-9-phenyl-7-(2-thienyl)pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-4(3H)-one 
• 847976-60-7 2-(3-amino-4-phenyl-6-(2-thienyl)thieno[2,3-b]pyridin-2-yl)-1,3,4-oxadiazole-5(4H)-thione 
• 847976-72-1 2-[1-(4-Chloro-phenyl)-meth-(E)-ylidene]-4-phenyl-6-thiophen-2-yl-thieno[2,3-b]pyridin-3-one 
• 723745-77-5 3-amino-2-methyl-9-phenyl-7-(2-thienyl)pyrido[3',2':4,5]-thieno[3,2-d]pyrimidine-4(3H)-one 
• 847976-54-9 N-(8-oxo-4-phenyl-2-thiophen-2-yl-8H-9-thia-1,5,7-triaza-fluoren-7-yl)-formimidic acid ethyl ester 
• 847976-57-2 3-amino-9-phenyl-7-(2-thienyl)pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-4(3H)-one 

Relevant articles and documents

Inhibitors of 15-Prostaglandin Dehydrogenase To Potentiate Tissue Repair

The enzyme 15-prostaglandin dehydrogenase (15-PGDH) catalyzes the first step in the degradation of prostaglandins including PGE2. It is a negative regulator of tissue repair and regeneration in multiple organs. Accordingly, inhibitors of 15-PGDH are anticipated to elevate in vivo levels of PGE2 and to promote healing and tissue regeneration. The small molecule SW033291 (1) inhibits 15-PGDH with Ki = 0.1 nM in vitro, doubles PGE2 levels in vivo, and shows efficacy in mouse models of recovery from bone marrow transplantation, ulcerative colitis, and partial hepatectomy. Here we describe optimized variants of 1 with improved solubility, druglike properties, and in vivo activity.

COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY

Compounds and methods of modulating 15-PGDH activity, modulating tissue prostaglandin levels, treating disease, diseases disorders, or conditions in which it is desired to modulate 15-PGDH activity and/or prostaglandin levels include 15-PGDH inhibitors and 15-PGDH activators described herein.

Synthesis and reactions of some new heterocyclic compounds containing the thienylthieno[2,3-b]pyridine moiety

(4-Aryl-3-cyano-6-(2-thienyl)pyridin-2-ylthio)acethydrazides (5a-c), 3-amino-4-aryl-6-(2-thienyl)thieno[2,3-b]pyridine-2-carbohydrazides (6a-c) and 3-amino-4-phenyl-6-(2-thienyl)thieno[2,3-b]pyridine-2-carboxylic acid (30) were prepared and employed as key intermediates in the synthesis of the title compounds.

Bicyclic heteroamatic compounds useful as LH agonists

The invention relates to a bicyclic heteroaromatic derivative compound according to general formula (I), or a pharmaceutically acceptable salt thereof, wherein R1is NR5R6, OR5, SR5or R7; R5and R6are independently selected from H, (1-8C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (3-8C)cycloalkyl, (2-7C)heterocycloalkyl, alkyl(1-8C)carbonyl, (6-14C)arylcarbonyl, (6-14C)aryl or (4-13C)heteroaryl, or R5and R6together are joined in a (2-7C)heterocloalkyl ring; R7is (3-8C)cycloalkyl, (2-7C)heterocycloalkyl, (6-14C)aryl or (4-13C)heteroaryl, R2is (1-8C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, or (6-14C)aryl or (4-13C)heteroaryl, both optionally substituted with one or more substituents selected from (1-8C)alkyl, (1-8C)alkylthio, (1-8C)(di)alkylamino, (1-8C)alkoxy, (2-8C)alkenyl, or (2-8C)alkynyl; R3is (1-8C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (3-8C)cycloalkyl, (2-7C)heterocycloalkyl, or (6-14C)aryl or (4-13C)heteroaryl, both optionally substituted with one or more substituents selected from (1-8C)alkyl, (1-8C)(di)alkylamino or (1-8C)alkoxy; X is S, O or N(R4); R4is H, (1-8C)alkyl, (1-8C)alkylcarbonyl, (6-14C)arylcarbonyl or (6-14C)aryl(1-8C)alkyl; Y is CH or N; Z is NH2or OH; A is S, N(H), N(R9), O or a bond; R9can be selected from the same groups as described for R2and B is N(H), O or a bond. The compounds of the invention have LH receptor activating activity and can be used in fertility regulating therapies.